SRS Capital Advisors Inc. Increases Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

SRS Capital Advisors Inc. raised its stake in DexCom, Inc. (NASDAQ:DXCM) by 1,304.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,753 shares of the medical device company’s stock after purchasing an additional 2,557 shares during the period. SRS Capital Advisors Inc.’s holdings in DexCom were worth $214,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in DXCM. Versant Capital Management Inc purchased a new position in DexCom in the fourth quarter valued at approximately $25,000. Private Trust Co. NA grew its position in shares of DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after acquiring an additional 245 shares during the last quarter. Heck Capital Advisors LLC purchased a new position in shares of DexCom during the fourth quarter worth approximately $38,000. Midwest Capital Advisors LLC purchased a new position in shares of DexCom during the fourth quarter worth approximately $54,000. Finally, RPg Family Wealth Advisory LLC purchased a new position in shares of DexCom during the third quarter worth approximately $57,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and raised their target price for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Morgan Stanley raised their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Canaccord Genuity Group raised their target price on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Finally, Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, DexCom has an average rating of “Moderate Buy” and a consensus price target of $99.82.

DexCom Price Performance

DexCom stock opened at $82.42 on Wednesday. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The business has a fifty day moving average of $84.86 and a two-hundred day moving average of $76.91. The company has a market cap of $32.21 billion, a P/E ratio of 57.64, a price-to-earnings-growth ratio of 2.30 and a beta of 1.14.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In other news, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the transaction, the chief operating officer now owns 268,644 shares of the company’s stock, valued at $23,347,850.04. The trade was a 0.97 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,083 shares of company stock valued at $3,309,794 in the last 90 days. 0.30% of the stock is currently owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.